Ambipar Emergency Ownership

AMBI Stock  USD 5.21  0.04  0.76%   
Ambipar Emergency holds a total of 16.2 Million outstanding shares. Ambipar Emergency Response shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 84.26 percent of Ambipar Emergency outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as Ambipar Emergency in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Ambipar Emergency, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ambipar Emergency Response. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

Ambipar Stock Ownership Analysis

About 84.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.25. Some equities with similar Price to Book (P/B) outperform the market in the long run. Ambipar Emergency had not issued any dividends in recent years. The entity had 1:1 split on the 6th of March 2023. Ambit Biosciences Corporationration, a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of oncology, autoimmune, and inflammatory diseases in the United States. For more info on Ambipar Emergency Response please contact the company at 55 11 3429 5000 or go to https://ir-response.ambipar.com.
Besides selling stocks to institutional investors, Ambipar Emergency also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Ambipar Emergency's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Ambipar Emergency's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Ambipar Emergency Quarterly Liabilities And Stockholders Equity

5.21 Billion

About 84.0% of Ambipar Emergency Response are currently held by insiders. Unlike Ambipar Emergency's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Ambipar Emergency's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Ambipar Emergency's insider trades

Ambipar Emergency Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ambipar Emergency insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ambipar Emergency's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ambipar Emergency insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
North Annette six days ago
Disposition of 66000 shares by North Annette of Ambipar Emergency at 11.81 subject to Rule 16b-3
 
Bonita David P over a week ago
Acquisition by Bonita David P of 100 shares of Ambipar Emergency at 6.7773 subject to Rule 16b-3
 
Foresite Capital Management I, Llc over two weeks ago
Acquisition by Foresite Capital Management I, Llc of 5700 shares of Ambipar Emergency at 7.4532 subject to Rule 16b-3
 
North Annette over three weeks ago
Acquisition by North Annette of 40000 shares of Ambipar Emergency at 10.8 subject to Rule 16b-3
 
Orbimed Advisors Llc over three months ago
Acquisition by Orbimed Advisors Llc of 10500 shares of Ambipar Emergency at 6.7773 subject to Rule 16b-3
 
Orbimed Advisors Llc over three months ago
Acquisition by Orbimed Advisors Llc of 367315 shares of Ambipar Emergency subject to Rule 16b-3
 
Bonita David P over three months ago
Acquisition by Bonita David P of 1730 shares of Ambipar Emergency subject to Rule 16b-3
 
Elms Steve over three months ago
Acquisition by Elms Steve of 2362 shares of Ambipar Emergency at 6.66 subject to Rule 16b-3
 
Bonfiglio John N over three months ago
Disposition of tradable shares by Bonfiglio John N of Ambipar Emergency subject to Rule 16b-3
 
Bonita David P over three months ago
Disposition of 50256 shares by Bonita David P of Ambipar Emergency subject to Rule 16b-3
 
Bonita David P over six months ago
Acquisition by Bonita David P of 1730 shares of Ambipar Emergency subject to Rule 16b-3
 
Bonfiglio John N over six months ago
Disposition of 20000 shares by Bonfiglio John N of Ambipar Emergency at 6.33 subject to Rule 16b-3

Ambipar Emergency Corporate Filings

6K
3rd of February 2025
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
31st of July 2024
Other Reports
ViewVerify

Currently Active Assets on Macroaxis

When determining whether Ambipar Emergency offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ambipar Emergency's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ambipar Emergency Response Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ambipar Emergency Response Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ambipar Emergency Response. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Environmental & Facilities Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ambipar Emergency. If investors know Ambipar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ambipar Emergency listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.77)
Earnings Share
0.13
Revenue Per Share
57.22
Quarterly Revenue Growth
0.578
Return On Assets
0.072
The market value of Ambipar Emergency is measured differently than its book value, which is the value of Ambipar that is recorded on the company's balance sheet. Investors also form their own opinion of Ambipar Emergency's value that differs from its market value or its book value, called intrinsic value, which is Ambipar Emergency's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ambipar Emergency's market value can be influenced by many factors that don't directly affect Ambipar Emergency's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ambipar Emergency's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ambipar Emergency is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ambipar Emergency's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.